Ocugen, Inc.
8.7M
$598.41M
-5.97
$-0.23
No price alerts set. Add an alert to get notified!
-5.97
-33.31
$-0.23
524.35%
-1,537.41%
-1,425.70%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics S.A.
|
$4.29 | 0.23% | -4.52 | $545.65M | -2.36 |
|
ALMS
Alumis Inc. Common Stock
|
$24.65 | -1.36% | -10.61 | $3.04B | 0.12 |
|
CMPX
Compass Therapeutics, Inc.
|
$5.65 | -5.82% | -15.71 | $782.22M | 0.05 |
|
FULC
Fulcrum Therapeutics, Inc.
|
$7.97 | -3.86% | -6.74 | $433.43M | 0.02 |
|
LCTX
Lineage Cell Therapeutics, Inc.
|
$1.69 | -1.46% | -6.10 | $419.71M | 0.05 |
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
$1.83 | -2.14% | -13.21 | $771.10M | 0.58 |
|
NGNE
Neurogene Inc.
|
$28.20 | 1.26% | -4.83 | $440.44M | 0.04 |
|
NMRA
Neumora Therapeutics, Inc. Common Stock
|
$2.17 | 0.70% | -1.49 | $394.12M | 0.00 |
|
OMER
Omeros Corporation
|
$13.28 | -1.19% | -251.77 | $956.11M | -1.97 |
|
RAPT
RAPT Therapeutics, Inc.
|
$58.01 | 0.00% | -14.81 | $959.26M | 0.02 |
* Peer stocks are selected based on market capitalization and sector
$2.73
$0.64
$0.00
0.00%
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
